Ariad Gets $12.5M From Merck For Beginning Cancer Trial

10/20/08Follow @xconomy

Ariad Pharmaceuticals, the Cambridge, MA-based developer of cancer drugs, said today it will receive a $12.5 million milestone payment from its partner, Merck, for beginning a mid-stage study of deforolimus for patients with advanced prostate cancer. The treatment, an oral pill, is being tested against other forms of cancer through the Merck partnership.

By posting a comment, you agree to our terms and conditions.